Tenax Therapeutics, Inc.

Tenax Therapeutics, Inc.

1.36
EUR
0.00
(0.00%)
-1.22EPS
Apr 01Next Earn
2014 Y
2015 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
331.87
56.13
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
-29,132.41
-16,038.51
- -
-50,027.23
-10,022.32
-5,967.95
-2,167.97
-1,520.75
-2,525.22
-600.72
-31.04
-1.15
-1.34
-1.38
Free Cash Flow per Basic Share
-10,656.75
-11,108.23
- -
-18,079.94
-13,769.9
-2,323.65
-1,952.42
-1,431.98
-844.59
-619.37
-23.76
-0.97
-0.91
-1.04
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
95,270.53
80,215.3
2.15
19,522.71
10,070.14
4,966.77
895.44
586.48
269.43
52.11
27.15
26.89
10.42
2.39
Tangible Book Value per Share
55,885.65
42,327.94
2.15
19,522.71
10,070.14
4,966.77
895.44
586.48
269.43
52.11
27.15
26.89
10.42
2.39
Basic Weighted Avg Shares
- -
- -
28
- -
- -
- -
- -
- -
- -
- -
- -
15
39
48
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
-5,753.25
-27,963.07
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
-20
-14
- -
-44
-9
-7
-8
-10
-32
-11
-8
-18
-53
-66
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-6,768.3
-28,571.63
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Working Capital
56
13
16
7
7
12
4
5
4
1
8
92
97
109
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
83
70
60
17
9
12
4
5
4
1
8
92
97
109
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-18.37
- -
-113.26
-67.94
-136.97
-108.01
-234.61
-732.21
-385.12
-160.8
-35.17
-55.64
-64.2

Capital Structure

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
24
32
46
Market Capitalization
- -
- -
- -

Working Capital

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
123
122
117
Cash, Cash Equivalents & STI
119
118
114
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
8
8
8
Payables & Accruals
8
7
7
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
127.83%
282.19%
5.52%
Free Cash Flow
- -
53.27%
141.71%
Net Income, GAAP
- -
92.11%
198.82%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-3.12
-1.83
-0.19
-0.18
-1.15
2025
-0.28
-0.27
-0.4
-0.38
-1.34
2026
-0.35
-0.35
-0.31
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Christopher T. Giordano
Full Time Employees
16
Sector
Health technology
Industry
Pharmaceuticals: major
Address
101 Glen Lennox Drive Chapel Hill NC United States 27517
IPO Date
Oct 28, 1993
Business
Tenax Therapeutics, Inc. (Nasdaq: TENX) is a Phase 3 development-stage pharmaceutical company focused on developing novel therapies for cardiopulmonary diseases, particularly pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF). The company develops TNX-103, an oral formulation of levosimendan that has completed Phase 2 trials for PH-HFpEF; TNX-201, an oral enteric-coated imatinib for pulmonary arterial hypertension (PAH); and earlier-stage candidates including TNX-101 and TNX-102 for related pulmonary hypertension indications. Founded in 1967 and headquartered in Chapel Hill, North Carolina, Tenax Therapeutics operates primarily in the United States with a small team of experts guiding its clinical programs targeting unmet needs in cardiovascular and pulmonary care. In August 2024, the company closed an oversubscribed $100 million private placement led by BVF Partners LP with participation from Venrock Healthcare Capital Partners, Vivo Capital, Janus Henderson Investors and others to fund the ongoing LEVEL Phase 3 trial of TNX-103 and initiate a second Phase 3 study in 2025, accelerating its path to NDA submission; this followed a $25 million private placement with RTW Investments in March 2025 to support clinical trials and operations.

Company News

  • SHAREHOLDER ALERT: Bronstein Gewirtz & Grossman, LLC Announces Class Action Against Tenax Therapeutics, Inc. (TENX) - Investors Who Suffered Losses Are Encouraged to Contact the Firm

  • TENX Investor Alert: Tenax Therapeutics, Inc. Securities Class Action Notice - Contact Levi & Korsinsky

  • INVESTOR REMINDER: Berger Montague Notifies Tenax Therapeutics, Inc. (NASDAQ: TENX) Investors of a Class Action Lawsuit and Deadline

  • Kaplan Fox Encourages Tenax Therapeutics, Inc. (TENX) Investors to Contact the Firm Before the Deadline on December 28, 2026 for a Leadership Role

  • ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Tenax Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - TENX

  • SHAREHOLDER ALERT: Bronstein Gewirtz & Grossman, LLC Announces Class Action Against Tenax Therapeutics, Inc. (NASDAQ: TENX) — Investors Who Suffered Losses Are Encouraged to Contact the Firm

  • ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Tenax Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - TENX

  • TENX DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Tenax Therapeutics (TENX) Investors of Securities Class Action Lawsuit Deadline on December 28, 2026

  • ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Tenax Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - TENX

  • ROSEN, A TOP RANKED LAW FIRM, Encourages Tenax Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - TENX

  • Kaplan Fox Advises Tenax Therapeutics, Inc. (TENX) Investors to Act Before the Lead Plaintiff Deadline on December 28, 2026

  • Did You Lose Money on Tenax Therapeutics, Inc. Stock? Faruqi & Faruqi, LLP Reminds Investors of December 28, 2026 Lead Plaintiff Deadline in Securities Class Action After 89.77% Share Price Decline

  • ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Tenax Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - TENX

  • DEADLINE ALERT for UP Fintech Holding Limited (TIGR), Tenax Therapeutics, Inc. (TENX), Everest Group, Ltd. (EG), and Yiren Digital Ltd.

  • TENX Investor Alert: Johnson Fistel Encourages Tenax Therapeutics, Inc. Investors to Contact the Firm Ahead of December 28, 2026 Lead Plaintiff Deadline

  • Pomerantz Law Firm Announces the Filing of a Class Action Against Tenax Therapeutics, Inc. and Certain Officers - TENX

  • TENX Deadline Alert: SueWallSt Reminds Tenax Therapeutics, Inc. (TENX) Investors of Securities Class Action Deadline on December 28, 2026

  • TENX UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Tenax Therapeutics (TENX) Investors of Securities Class Action Lawsuit Deadline on December 28, 2026

  • Deadline Alert: Tenax Therapeutics, Inc. Investors Have Until December 28, 2026 to Seek Lead Plaintiff Role in Securities Fraud Class Action, Glancy Prongay Wolke & Rotter LLP Reminds Investors

  • ROSEN, A TOP-RANKED LAW FIRM, Encourages Tenax Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - TENX